You are here: Industry Insights > IDMC

News List

DiscGenics Completes Patient Enrollment in Japanese Clinical Study of Cell Therapy for Disc Degeneration as US Study Achieves One-Year Follow-up Milestone prnasia
April 27, 2021
DiscGenics, Inc. today announced that it has completed enrollment in its Japanese safety study of IDCT, an allogeneic, injectable Discogenic Cell therapy for lumbar disc degeneration, a major cause of chronic low back pain.
Roche ends tominersen study in manifest Huntington’s disease pharmatimes
March 24, 2021
Swiss pharma company Roche has announced that it will discontinue dosing in a Phase III study evaluating its investigational candidate tominersen in manifest Huntington’s disease.
Libtayo Monotherapy Trial in Advanced Cervical Cancer Stopped Early for OS Positive Result americanpharmaceuticalreview
March 22, 2021
Regeneron Pharmaceuticals and Sanofi announced positive results demonstrating an overall survival (OS) benefit from the Phase 3 trial investigating the PD-1 inhibitor Libtayo® (cemiplimab) monotherapy compared to chemotherapy, in patients previously ...
Libtayo® improves overall survival in advanced cervical cancer patients europeanpharmaceuticalreview
March 16, 2021
A Phase III trial evaluating Libtayo® (cemiplimab) monotherapy in advanced cervical cancer has been stopped early due to a positive result on overall survival.
Panel finds efficacy for Regeneron’s REGEN-COV in Phase III Covid-19 trial pharmaceutical-technology
March 01, 2021
Regeneron Pharmaceuticals has announced that Independent Data Monitoring Committee (IDMC) found its REGEN-COV antibody cocktail to have clear clinical efficacy in cutting down the rates of hospitalisation and deaths in patients in a Phase III Covid-19 ...
IDMC Concluded Lynparza Trial Crossed Superiority Boundary for Invasive Disease-Free Survival americanpharmaceuticalreview
February 20, 2021
The OlympiA Phase III trial for AstraZeneca and MSD’s Lynparza will move to early primary analysis and reporting following a recommendation from the Independent Data Monitoring Committee (IDMC).
Lynparza crosses superiority boundary for invasive disease-free survival at interim analysis europeanpharmaceuticalreview
February 19, 2021
The OlympiA trial will conduct its primary analysis early, after the Independent Data Monitoring Committee found it met its primary endpoint in BRCA mutated early breast cancer patients.
IDMC recommends modifications to Regeneron COVID-19 antibody trial europeanpharmaceuticalreview
November 06, 2020
The clinical trial testing the REGN-COV2 antibody cocktail should be altered, according to the Independent Data Monitoring Committee (IDMC).
Chi-Med’s Surufatinib Study Meets Primary Endpoint Early contractpharma
July 04, 2019
Stops Phase III study of surufatinib in advanced neuroendocrine tumors, meeting the primary endpoint of progression free survival.
IDMC Recommends Stopping Depatuxizumab Mafodotin Study americanpharmaceuticalreview
May 23, 2019
AbbVie announced the Phase 3 INTELLANCE-1 study of depatuxizumab mafodotin (Depatux-M, previously known as ABT-414) in patients with newly diagnosed glioblastoma (GBM) ...